Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Lifileucel heads up the list of upcoming US FDA catalysts.
Private company trial initiations stand out in the latest week’s disclosures.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Despite magrolimab’s latest flop, efforts to target CD47 continue.